BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fiorino S, Bacchi-Reggiani ML, Visani M, Acquaviva G, Fornelli A, Masetti M, Tura A, Grizzi F, Zanello M, Mastrangelo L, Lombardi R, Di Tommaso L, Bondi A, Sabbatani S, Domanico A, Fabbri C, Leandri P, Pession A, Jovine E, de Biase D. MicroRNAs as possible biomarkers for diagnosis and prognosis of hepatitis B- and C-related-hepatocellular-carcinoma. World J Gastroenterol 2016; 22(15): 3907-3936 [PMID: 27099435 DOI: 10.3748/wjg.v22.i15.3907] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 35] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 An Y, Gao S, Zhao WC, Qiu BA, Xia NX, Zhang PJ, Fan ZP. Novel serum microRNAs panel on the diagnostic and prognostic implications of hepatocellular carcinoma. World J Gastroenterol 2018; 24(24): 2596-2604 [PMID: 29962816 DOI: 10.3748/wjg.v24.i24.2596] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
2 Shi DM, Bian XY, Qin CD, Wu WZ. miR-106b-5p promotes stem cell-like properties of hepatocellular carcinoma cells by targeting PTEN via PI3K/Akt pathway. Onco Targets Ther 2018;11:571-85. [PMID: 29416358 DOI: 10.2147/OTT.S152611] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 7.5] [Reference Citation Analysis]
3 Fang M, Zheng WJ, Yao M, Dong ZZ, Yao DF. Novel specific markers for hepatocellular carcinoma: Perspective on clinical applications. Shijie Huaren Xiaohua Zazhi 2017; 25(10): 865-873 [DOI: 10.11569/wcjd.v25.i10.865] [Cited by in CrossRef: 1] [Article Influence: 0.2] [Reference Citation Analysis]
4 El-Hamouly MS, Azzam AA, Ghanem SE, El-Bassal FI, Shebl N, Shehata AMF. Circulating microRNA-301 as a promising diagnostic biomarker of hepatitis C virus-related hepatocellular carcinoma. Mol Biol Rep 2019;46:5759-65. [PMID: 31471732 DOI: 10.1007/s11033-019-05009-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
5 Xian Y, Wang L, Yao B, Yang W, Mo H, Zhang L, Tu K. MicroRNA-769-5p contributes to the proliferation, migration and invasion of hepatocellular carcinoma cells by attenuating RYBP. Biomed Pharmacother 2019;118:109343. [PMID: 31545279 DOI: 10.1016/j.biopha.2019.109343] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
6 Zhang P, Yu J, Gui Y, Sun C, Han W. Inhibition of miRNA-222-3p Relieves Staphylococcal Enterotoxin B-Induced Liver Inflammatory Injury by Upregulating Suppressors of Cytokine Signaling 1. Yonsei Med J 2019;60:1093-102. [PMID: 31637892 DOI: 10.3349/ymj.2019.60.11.1093] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
7 Sultana C, Rosca A, Ruta S. Correlation Between miR-125b Expression and Liver Fibrosis in Patients with Chronic Hepatitis C. Hepat Mon 2019;In Press. [DOI: 10.5812/hepatmon.84615] [Reference Citation Analysis]
8 Wang G, Mao BJ. Mechanisms for microRNAs in pathogenesis of hepatocellular carcinoma and challenges in their clinical application. Shijie Huaren Xiaohua Zazhi 2016; 24(33): 4430-4437 [DOI: 10.11569/wcjd.v24.i33.4430] [Reference Citation Analysis]
9 Du B, Zhang P, Tan Z, Xu J. MiR-1202 suppresses hepatocellular carcinoma cells migration and invasion by targeting cyclin dependent kinase 14. Biomed Pharmacother 2017;96:1246-52. [PMID: 29217161 DOI: 10.1016/j.biopha.2017.11.090] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
10 Miquelestorena-standley E, Tallet A, Collin C, Piver E, De Muret A, Salamé E, Bourlier P, Kervarrec T, Guyétant S, Pagès J. Interest of variations in microRNA-152 and -122 in a series of hepatocellular carcinomas related to hepatitis C virus infection: MicroRNA in hepatocellular carcinoma. Hepatol Res 2018;48:566-73. [DOI: 10.1111/hepr.12915] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
11 Cahová M, Daňková H, Heczková M, Brátová M, Ďásková N, Baštová H, Gojda J, Wohl P. MicroRNAs as potential markers of parenteral nutrition associated liver disease in adult patients. Physiol Res 2019;68:681-8. [PMID: 31177800 DOI: 10.33549/physiolres.934103] [Reference Citation Analysis]
12 Fiorino S, Di Saverio S, Leandri P, Tura A, Birtolo C, Silingardi M, de Biase D, Avisar E. The role of matricellular proteins and tissue stiffness in breast cancer: a systematic review. Future Oncology 2018;14:1601-27. [DOI: 10.2217/fon-2017-0510] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
13 Yang G, Xu Q, Wan Y, Zhang L, Wang L, Meng F. Circ-CSPP1 knockdown suppresses hepatocellular carcinoma progression through miR-493-5p releasing-mediated HMGB1 downregulation. Cell Signal 2021;86:110065. [PMID: 34182091 DOI: 10.1016/j.cellsig.2021.110065] [Reference Citation Analysis]
14 Luo YH, Tang W, Zhang X, Tan Z, Guo WL, Zhao N, Pang SM, Dang YW, Rong MH, Cao J. Promising significance of the association of miR-204-5p expression with clinicopathological features of hepatocellular carcinoma. Medicine (Baltimore) 2017;96:e7545. [PMID: 28746200 DOI: 10.1097/MD.0000000000007545] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
15 Zhang S, Chen L, Wang Y, Tang W, Chen Y, Liu L. Investigation of the Association of miRNA-499, miRNA-146a, miRNA-196a2 Loci with Hepatocellular Carcinoma Risk: A Case-Control Study Involving 1507 Subjects. DNA Cell Biol 2020;39:379-88. [PMID: 32031872 DOI: 10.1089/dna.2019.5145] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Loosen SH, Wirtz TH, Roy S, Vucur M, Castoldi M, Schneider AT, Koppe C, Ulmer TF, Roeth AA, Bednarsch J, Alizai PH, Paffenholz P, Demir M, Trautwein C, Tacke F, Neumann UP, Roderburg C, Luedde T. Circulating levels of microRNA193a-5p predict outcome in early stage hepatocellular carcinoma. PLoS One 2020;15:e0239386. [PMID: 32960907 DOI: 10.1371/journal.pone.0239386] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
17 Wang X, Wen X, Zhou J, Qi Y, Wu R, Wang Y, Kui Y, Hua R, Jin Q. MicroRNA-223 and microRNA-21 in peripheral blood B cells associated with progression of primary biliary cholangitis patients. PLoS One 2017;12:e0184292. [PMID: 28886078 DOI: 10.1371/journal.pone.0184292] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
18 Zhang Y, Lin J, Huang W, Cao Y, Liu Y, Wang T, Zhong W, Wang D, Mao R, Chen X. The effect of circulating miR-223 on surveillance of different cancers: a meta-analysis. Onco Targets Ther 2017;10:3193-201. [PMID: 28721069 DOI: 10.2147/OTT.S137837] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
19 Gao Y, Gu J, Wang Y, Fu D, Zhang W, Zheng G, Wang X. Hepatitis B virus X protein boosts hepatocellular carcinoma progression by downregulating microRNA-137. Pathol Res Pract 2020;216:152981. [PMID: 32527447 DOI: 10.1016/j.prp.2020.152981] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Dubey SR, Ashavaid TF, Abraham P, Paradkar MU. Factors influencing circulating microRNAs as biomarkers for liver diseases. Mol Biol Rep. [DOI: 10.1007/s11033-022-07170-1] [Reference Citation Analysis]
21 Tuo H, Wang Y, Wang L, Yao B, Li Q, Wang C, Liu Z, Han S, Yin G, Tu K, Liu Q. MiR-324-3p promotes tumor growth through targeting DACT1 and activation of Wnt/β-catenin pathway in hepatocellular carcinoma. Oncotarget 2017;8:65687-98. [PMID: 29029464 DOI: 10.18632/oncotarget.20058] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
22 Tao J, Jiang L, Chen X. Roles of microRNA in liver cancer. Liver Research 2018;2:61-72. [DOI: 10.1016/j.livres.2018.06.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
23 Nadda N, Paul SB, Yadav DP, Kumar S, Sreenivas V, Saraya A, Gamanagatti S, Acharya SK, Shalimar, Nayak B. Prognostic and Therapeutic Potentials of OncomiRs Modulating mTOR Pathways in Virus-Associated Hepatocellular Carcinoma. Front Oncol 2020;10:604540. [PMID: 33614488 DOI: 10.3389/fonc.2020.604540] [Reference Citation Analysis]
24 Bharali D, Banerjee BD, Bharadwaj M, Husain SA, Kar P. Expression Analysis of MicroRNA-21 and MicroRNA-122 in Hepatocellular Carcinoma. J Clin Exp Hepatol 2019;9:294-301. [PMID: 31360021 DOI: 10.1016/j.jceh.2018.07.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
25 Safdar M, Zaheer S, Khailany RA, Parvez S, Naveed M, Bhuiyan P, Ozaslan M, Moatasam R, Al-Attar MS, Khan MA, Junejo Y. The Relevance of SNPs at 3'UTR Region of CASP7 and miR-371b-5p Associated Diseases: A Computational Analysis. Cell Biochem Biophys 2020;78:541-57. [PMID: 32951155 DOI: 10.1007/s12013-020-00941-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Zhang R, Zhang LJ, Yang ML, Huang LS, Chen G, Feng ZB. Potential role of microRNA‑223‑3p in the tumorigenesis of hepatocellular carcinoma: A comprehensive study based on data mining and bioinformatics. Mol Med Rep 2018;17:2211-28. [PMID: 29207133 DOI: 10.3892/mmr.2017.8167] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
27 Wang L, Wu J, Xie C. miR-92a promotes hepatocellular carcinoma cells proliferation and invasion by FOXA2 targeting. Iran J Basic Med Sci 2017;20:783-90. [PMID: 28852443 DOI: 10.22038/IJBMS.2017.9010] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
28 Dong X, Ding W, Ye J, Yan D, Xue F, Xu L, Yin J, Guo W. MiR-24-3p enhances cell growth in hepatocellular carcinoma by targeting metallothionein 1M. Cell Biochem Funct 2016;34:491-6. [PMID: 27650047 DOI: 10.1002/cbf.3213] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
29 Yuan F, Li Z, Chen L, Zeng T, Zhang YH, Ding S, Huang T, Cai YD. Identifying the Signatures and Rules of Circulating Extracellular MicroRNA for Distinguishing Cancer Subtypes. Front Genet 2021;12:651610. [PMID: 33767734 DOI: 10.3389/fgene.2021.651610] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Sanjay S, Girish C. Role of miRNA and its potential as a novel diagnostic biomarker in drug-induced liver injury. Eur J Clin Pharmacol 2017;73:399-407. [PMID: 28028586 DOI: 10.1007/s00228-016-2183-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
31 Kumar S, Williams D, Sur S, Wang JY, Jo H. Role of flow-sensitive microRNAs and long noncoding RNAs in vascular dysfunction and atherosclerosis. Vascul Pharmacol 2019;114:76-92. [PMID: 30300747 DOI: 10.1016/j.vph.2018.10.001] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 14.0] [Reference Citation Analysis]
32 Tepus M, Yau TO. Non-Invasive Colorectal Cancer Screening: An Overview. Gastrointest Tumors 2020;7:62-73. [PMID: 32903904 DOI: 10.1159/000507701] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
33 Zhang X, Ma L, Zhai L, Chen D, Li Y, Shang Z, Zhang Z, Gao Y, Yang W, Li Y, Pan Y. Construction and validation of a three-microRNA signature as prognostic biomarker in patients with hepatocellular carcinoma. Int J Med Sci 2021;18:984-99. [PMID: 33456356 DOI: 10.7150/ijms.49126] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Carossino M, Dini P, Kalbfleisch TS, Loynachan AT, Canisso IF, Shuck KM, Timoney PJ, Cook RF, Balasuriya UBR. Downregulation of MicroRNA eca-mir-128 in Seminal Exosomes and Enhanced Expression of CXCL16 in the Stallion Reproductive Tract Are Associated with Long-Term Persistence of Equine Arteritis Virus. J Virol 2018;92:e00015-18. [PMID: 29444949 DOI: 10.1128/JVI.00015-18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
35 Shi BM, Lu W, Ji K, Wang YF, Xiao S, Wang XY. Study on the value of serum miR-106b for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol 2017; 23(20): 3713-3720 [PMID: 28611524 DOI: 10.3748/wjg.v23.i20.3713] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
36 Ma Y, Ma M, Ma L, Zhang F, Liu Y, Ma X. Downregulation of miR-552 in hepatocellular carcinoma inhibits cell migration and invasion, and promotes cell apoptosis via RUNX3. Exp Ther Med 2019;18:3829-36. [PMID: 31656538 DOI: 10.3892/etm.2019.8061] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
37 Dundar HZ, Aksoy F, Aksoy SA, Tasar P, Ugras N, Tunca B, Egeli U, Cecener G, Yerci O, Kaya E. Overexpression of miR-21 Is Associated With Recurrence in Patients With Hepatitis B Virus-Mediated Hepatocellular Carcinoma Undergoing Liver Transplantation. Transplant Proc 2019;51:1157-61. [PMID: 31101191 DOI: 10.1016/j.transproceed.2019.01.089] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]